Literature DB >> 8525285

The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin.

K Awadzi1, N O Opoku, E T Addy, B T Quartey.   

Abstract

Ivermectin is the drug of choice for the treatment of onchocerciasis. However at the recommended dose of 150 micrograms/kg, it neither kills nor permanently sterilises the adult worms. We investigated whether high doses given with and without a preceding 150 micrograms/kg 'clearing' dose would be tolerable as well as effective against the adult worms. Seventy-five healthy males with moderate to heavy infections with Onchocerca volvulus were enrolled in a double-blind trial to receive one of the following treatment regimens: 150 micrograms/kg followed by placebo (9 patients); 400 micrograms/kg with (9 patients) or without (16 patients) a clearing dose; 600 micrograms/kg with (8 patients) or without (16 patients) a clearing dose and 800 micrograms/kg with (8 patients) or without (9 patients) a clearing dose. Detailed examinations were conducted before and at various times after treatment. A preliminary report on the clinical and laboratory safety as at 30 days is presented. All the regimens were well tolerated. No clinical or laboratory drug related effects were observed. The overall severity of the Mazzotti reaction was similar in all groups. Ocular reactions were minimal and there were no changes in ocular function or in fluorescein angiograms. The groups were similar in the extent of microfilaricidal activity; there was however a suggestion that microfilariae were killed more rapidly at 400 micrograms/kg and 600 micrograms/kg but not at 800 micrograms/kg. This needs further study. Single doses of ivermectin up to 800 micrograms/kg are well tolerated; no special precautions for treatment monitoring are required and a 'clearing' dose is not necessary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525285

Source DB:  PubMed          Journal:  Trop Med Parasitol        ISSN: 0177-2392


  17 in total

1.  Identifying sub-optimal responses to ivermectin in the treatment of River Blindness.

Authors:  Thomas S Churcher; Sébastien D S Pion; Mike Y Osei-Atweneboana; Roger K Prichard; Kwablah Awadzi; Michel Boussinesq; Richard C Collins; James A Whitworth; María-Gloria Basáñez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

2.  Nodding syndrome in Mundri county, South Sudan: environmental, nutritional and infectious factors.

Authors:  P S Spencer; K Vandemaele; M Richer; V S Palmer; S Chungong; M Anker; Y Ayana; M L Opoka; B N Klaucke; A Quarello; J K Tumwine
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

Review 3.  Ivermectin: a complimentary weapon against the spread of malaria?

Authors:  Haoues Alout; Brian D Foy
Journal:  Expert Rev Anti Infect Ther       Date:  2016-12-29       Impact factor: 5.091

Review 4.  Broadening the range of use cases for ivermectin - a review of the evidence.

Authors:  Christian Kositz; John Bradley; Harry Hutchins; Anna Last; Umberto D'Alessandro; Michael Marks
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-03-02       Impact factor: 2.455

5.  Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle.

Authors:  Barend M deC Bronsvoort; Alfons Renz; Virginia Tchakouté; Vincent N Tanya; David Ekale; Alexander J Trees
Journal:  Filaria J       Date:  2005-08-08

6.  Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

Authors:  Michel Boussinesq; Jacques Gardon; Nathalie Gardon-Wendel; Jean-Philippe Chippaux
Journal:  Filaria J       Date:  2003-10-24

7.  Diagnosis of O. volvulus infection via skin exposure to diethylcarbamazine: clinical evaluation of a transdermal delivery technology-based patch.

Authors:  K Awadzi; Nicholas O Opoku; Simon K Attah; Janis K Lazdins-Helds; Annette C Kuesel
Journal:  Parasit Vectors       Date:  2015-10-09       Impact factor: 3.876

8.  Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination.

Authors:  Carlos J Chaccour; Kevin C Kobylinski; Quique Bassat; Teun Bousema; Chris Drakeley; Pedro Alonso; Brian D Foy
Journal:  Malar J       Date:  2013-05-07       Impact factor: 2.979

9.  UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle.

Authors:  Barend M Dec Bronsvoort; Benjamin L Makepeace; Alfons Renz; Vincent N Tanya; Lawrence Fleckenstein; David Ekale; Alexander J Trees
Journal:  Parasit Vectors       Date:  2008-06-20       Impact factor: 3.876

10.  A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.

Authors:  Kwablah Awadzi; Nicholas O Opoku; Simon K Attah; Janis Lazdins-Helds; Annette C Kuesel
Journal:  PLoS Negl Trop Dis       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.